Irinotecan in the first-line treatment of colorectal cancer Conference Paper


Author: Saltz, L. B.
Title: Irinotecan in the first-line treatment of colorectal cancer
Conference Title: Clinical Status and Future Directions of Irinotecan
Abstract: Irinotecan (CPT-11 [Camptosar]) is currently approved for use as a second-line agent in the treatment of metastatic colorectal cancer. Phase II studies have also shown substantial single-agent activity of irinotecan in the first-line treatment of metastatic colorectal cancer. Response rates appear to be similar to those seen with standard first-line regimens, although direct randomized comparisons have not yet been reported. In the absence of definitive data showing irinotecan to be superior, its routine use as a single agent in the first-line treatment of colorectal cancer may be hard to justify, given the significant cost differential between irinotecan and current standard first-line regimens. Studies exploring combinations of irinotecan with fluorouracil may identify a first-line role for these combination regimens. Also, use of specific molecular markers may permit the identification of selected patients with tumor characteristics that would specifically favor consideration of upfront irinotecan monotherapy.
Keywords: cancer chemotherapy; clinical trial; fluorouracil; diarrhea; dose response; patient selection; conference paper; gemcitabine; paclitaxel; cancer adjuvant therapy; chemotherapy, adjuvant; cancer staging; colorectal cancer; antineoplastic agents, phytogenic; camptothecin; antineoplastic activity; docetaxel; irinotecan; colorectal neoplasms; drug cost; messenger rna; folinic acid; loperamide; navelbine; thymidylate synthase; intravenous drug administration; humans; human
Journal Title Oncology (Norwalk)
Volume: 12
Issue: 8 Suppl. 6
Conference Dates: 1998 Jan 21-23
Conference Location: Houston, TX
ISBN: 0890-9091
Publisher: C M P Medica LLC * The Oncology Group  
Date Published: 1998-08-01
Start Page: 54
End Page: 58
Language: English
PUBMED: 9726092
PROVIDER: scopus
DOI/URL:
Notes: Conference Paper -- Export Date: 12 December 2016 -- Source: Scopus
Citation Impact
MSK Authors
  1. Leonard B Saltz
    790 Saltz